Figure 6

Macroscopic appearance of papillomas from mice treated topically with TPA (1 μg/200 μl acetone, twice weekly) for 27 weeks, followed by an additional 3 weeks of TPA treatment alone ( A ), 3 weeks of TPA co-administered with 0.3 μM Sorafenib applied directly to the tumors ( B ) or TPA with 30 mg/kg Sorafenib administered by oral gavage ( C ). H&E staining of 30 week TPA treated skin (D), papillomas treated with TPA alone (E), TPA + topical Sorafenib (F), and TPA + oral gavage administered Sorafenib (G). H. IHC staining of papillomas from mice treated topically with TPA for 27 weeks, followed by an additional 3 weeks of TPA treatment alone (left panel), 3 weeks of TPA co-administered with topical 0.3 μM Sorafenib (middle panel) or TPA with 30 mg/kg Sorafenib administered by oral gavage (right panel). Sections were probed with an anti-pErk1/2 antibody followed by an Alexa-546 labeled secondary antibody, and counterstained with DAPI. Sections were photographed at 600× magnification.